Renaissance Technologies’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-6,642
Closed -$292K – 3511
2016
Q4
$292K Sell
6,642
-209
-3% -$6.66K ﹤0.01% 2919
2016
Q3
$110K Buy
6,851
+237
+4% +$6.55K ﹤0.01% 3169
2016
Q2
$218K Buy
6,614
+29
+0.4% +$1.09K ﹤0.01% 3026
2016
Q1
$184K Buy
6,585
+51
+0.8% +$1.36K ﹤0.01% 3111
2015
Q4
$304K Sell
6,534
-19
-0.3% -$2.12K ﹤0.01% 2883
2015
Q3
$1.17M Buy
6,553
+34
+0.5% +$6.7K ﹤0.01% 2303
2015
Q2
$932K Sell
6,519
-7
-0.1% -$971 ﹤0.01% 2481
2015
Q1
$881K Sell
6,526
-157
-2% -$25.7K ﹤0.01% 2372
2014
Q4
$1.2M Buy
6,683
+1,207
+22% +$215K ﹤0.01% 2053
2014
Q3
$1.31M Buy
5,476
+167
+3% +$55.8K ﹤0.01% 1896
2014
Q2
$2.33M Buy
5,309
+52
+1% +$24K 0.01% 1650
2014
Q1
$2.41M Sell
5,257
-52
-1% -$27K 0.01% 1667
2013
Q4
$2.55M Buy
5,309
+14
+0.3% +$6.84K 0.01% 1613
2013
Q3
$2.55M Buy
5,295
+21
+0.4% +$10.1K 0.01% 1542
2013
Q2
$2.48M Buy
+5,274
New +$2.39M 0.01% 1469

Other funds holding IDXG

Renaissance Technologies's IDXG Position: Q1 2017 in Review

Renaissance Technologies sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2017, closing a stake of 6,642 shares — an estimated $292K sold.

Renaissance Technologies first reported a position in IDXG in Q2 2013 and held it in 15 quarters. The position peaked at $2.55M in Q4 2013. 16 funds tracked by Wall St. Rank hold IDXG as of Q1 2017.

  • Renaissance Technologies reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Renaissance Technologies sold 6,642 Interpace Biosciences, Inc. Common Stock shares in Q1 2017, an estimated $292K.
  • Renaissance Technologies first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
  • Renaissance Technologies's Interpace Biosciences, Inc. Common Stock position peaked at $2.55M in Q4 2013.
  • 16 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2017.

Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.